The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy.
cancer
lung cancer
molecular oncology
mutation—genetics
thyroid cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
05
2019
accepted:
25
11
2019
entrez:
11
1
2020
pubmed:
11
1
2020
medline:
11
1
2020
Statut:
epublish
Résumé
The diagnosis of the primary origin of metastases to the thyroid gland is not easy, in particular in case of concomitant lung adenocarcinoma which shares several immunophenotypical features. Although rare, these tumors should be completely characterized in order to set up specific therapies. This is the case of a 64-years-old woman referred to our institution for a very advanced neoplastic disease diagnosed both as poorly differentiated/anaplastic thyroid cancer (PDTC/ATC) for the huge involvement of the neck and concomitant lung adenocarcinoma (LA). Neither the clinical features and the imaging evaluation nor the tumor markers allowed a well-defined diagnosis. Moreover, the histologic features of the thyroid and lung biopsies confirmed the synchronous occurrence of two different tumors. The molecular analysis showed a c.34G>T (p.G12C) mutation in the codon 12 of K-RAS gene, in both tissues. Since, this mutation is highly prevalent in LA and virtually absent in PDTC/ATC the lung origin of the malignancy was assumed, and the patient was addressed to the correct therapeutic strategy.
Identifiants
pubmed: 31921647
doi: 10.3389/fonc.2019.01390
pmc: PMC6928194
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1390Informations de copyright
Copyright © 2019 Matrone, Torregrossa, Sensi, Cappellani, Baronti, Ciampi, Molinaro, Ugolini, Aghababyan, De Napoli, Latrofa, Materazzi, Basolo, Vitti and Elisei.
Références
Clin Cancer Res. 2018 Jul 1;24(13):3059-3068
pubmed: 29615459
J Clin Invest. 2016 Mar 1;126(3):1052-66
pubmed: 26878173
Clin Endocrinol (Oxf). 2007 Apr;66(4):565-71
pubmed: 17371476
Clin Endocrinol (Oxf). 2005 Feb;62(2):236-41
pubmed: 15670202
Am J Clin Oncol. 2015 Aug;38(4):338-42
pubmed: 23799287
Semin Oncol. 1977 Mar;4(1):59-64
pubmed: 841351
Mol Cancer Ther. 2018 Jul;17(7):1575-1584
pubmed: 29695638
J Clin Oncol. 2018 Jan 1;36(1):7-13
pubmed: 29072975
J Natl Cancer Inst. 1984 Jun;72(6):1271-5
pubmed: 6328090
Ann Surg Oncol. 2017 Jun;24(6):1533-1539
pubmed: 27873099
Eur J Surg Oncol. 2004 Aug;30(6):583-8
pubmed: 15256229
Diagn Cytopathol. 2015 Jul;43(7):585-9
pubmed: 25900221
Cell. 2014 Oct 23;159(3):676-90
pubmed: 25417114
Eur J Endocrinol. 2012 Dec;167(6):793-7
pubmed: 22989467
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Cancer. 1962 May-Jun;15:557-65
pubmed: 13911946
Am J Surg Pathol. 2002 Jun;26(6):767-73
pubmed: 12023581
Arch Pathol Lab Med. 1998 Jan;122(1):37-41
pubmed: 9448014
J Cardiothorac Surg. 2013 May 17;8:131
pubmed: 23684153
Oncol Lett. 2018 Jun;15(6):9174-9182
pubmed: 29805648
JAMA Oncol. 2016 Jun 1;2(6):805-12
pubmed: 27100819
Eur J Cancer. 2018 Aug;99:20-27
pubmed: 29894909
Cancer Res. 1993 Jan 1;53(1):61-6
pubmed: 7677981
Diagn Interv Radiol. 2017 Mar-Apr;23(2):118-126
pubmed: 28206951